IT9068053A0 - Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi e terapia di affezioni tumorali e suo impiego - Google Patents

Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi e terapia di affezioni tumorali e suo impiego

Info

Publication number
IT9068053A0
IT9068053A0 IT9068053A IT6805390A IT9068053A0 IT 9068053 A0 IT9068053 A0 IT 9068053A0 IT 9068053 A IT9068053 A IT 9068053A IT 6805390 A IT6805390 A IT 6805390A IT 9068053 A0 IT9068053 A0 IT 9068053A0
Authority
IT
Italy
Prior art keywords
avidin
biotin
diagnosis
therapy
monoclonal antibodies
Prior art date
Application number
IT9068053A
Other languages
English (en)
Other versions
IT1245748B (it
IT9068053A1 (it
Inventor
Giovanni Paganelli
Antonio Siccardi
Massimo Malcovati
Gianalfredo Scassellati
Ferruccio Fazio
Original Assignee
Mini Ricerca Scient Tecnolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mini Ricerca Scient Tecnolog filed Critical Mini Ricerca Scient Tecnolog
Priority to IT06805390A priority Critical patent/IT1245748B/it
Publication of IT9068053A0 publication Critical patent/IT9068053A0/it
Priority to EP91121419A priority patent/EP0496074B1/en
Priority to DE69123235T priority patent/DE69123235T2/de
Publication of IT9068053A1 publication Critical patent/IT9068053A1/it
Application granted granted Critical
Publication of IT1245748B publication Critical patent/IT1245748B/it

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IT06805390A 1990-12-21 1990-12-21 Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi di affezioni tumorali e suo impiego IT1245748B (it)

Priority Applications (3)

Application Number Priority Date Filing Date Title
IT06805390A IT1245748B (it) 1990-12-21 1990-12-21 Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi di affezioni tumorali e suo impiego
EP91121419A EP0496074B1 (en) 1990-12-21 1991-12-13 Biotinylated monoclonal antibodies, avidin and biotin for diagnosis and therapy
DE69123235T DE69123235T2 (de) 1990-12-21 1991-12-13 Biotinylierte monoklonale Antikörper, Avidin und Biotin für die Diagnose und Therapie

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT06805390A IT1245748B (it) 1990-12-21 1990-12-21 Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi di affezioni tumorali e suo impiego

Publications (3)

Publication Number Publication Date
IT9068053A0 true IT9068053A0 (it) 1990-12-21
IT9068053A1 IT9068053A1 (it) 1992-06-22
IT1245748B IT1245748B (it) 1994-10-14

Family

ID=11307501

Family Applications (1)

Application Number Title Priority Date Filing Date
IT06805390A IT1245748B (it) 1990-12-21 1990-12-21 Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi di affezioni tumorali e suo impiego

Country Status (3)

Country Link
EP (1) EP0496074B1 (it)
DE (1) DE69123235T2 (it)
IT (1) IT1245748B (it)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6075010A (en) * 1992-06-09 2000-06-13 Neorx Corporation Small molecular weight ligand-hexose containing clearing agents
US6416738B1 (en) 1973-12-07 2002-07-09 Neorx Corporation Pretargeting methods and compounds
US5525338A (en) * 1992-08-21 1996-06-11 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin conjugates
US5976535A (en) * 1992-06-09 1999-11-02 Neorx Corporation Pretargeting protocols for the enhanced localization of cytotoxins to target sites and cytotoxic combinations useful therefore
US5624896A (en) * 1992-06-09 1997-04-29 Neorx Corporation Clearing agents useful in pretargeting methods
US5914312A (en) * 1992-06-09 1999-06-22 Neorx Corporation Pretargeting methods and compounds
US6358490B2 (en) 1992-06-09 2002-03-19 Neorx Corporation Three-step pretargeting methods and compounds
EP0646019B9 (en) * 1992-06-09 2002-12-18 Neorx Corporation Biotin-DOTA conjugates and their use in pretargeting methods
US5911969A (en) 1992-06-09 1999-06-15 Neorx Corporation Pretargeting protocols for enhanced localization of active agents to target sites
US6022966A (en) * 1993-11-22 2000-02-08 Neorx Corporation Pretargeting methods and compounds
US5578287A (en) * 1992-06-09 1996-11-26 Neorx Corporation Three-step pretargeting methods using improved biotin-active agent
US5616690A (en) * 1992-06-09 1997-04-01 Neorx Corporation Hexose derivatized human serum albumin clearing agents
US6217869B1 (en) 1992-06-09 2001-04-17 Neorx Corporation Pretargeting methods and compounds
US5541287A (en) * 1992-06-09 1996-07-30 Neorx Corporation Pretargeting methods and compounds
GB2289679B (en) * 1993-01-15 1997-02-05 Imp Cancer Res Tech Compounds comprising a target cell-specific portion and a portion which has DNA endonucleolytic activity, and uses thereof
GB9300686D0 (en) * 1993-01-15 1993-03-03 Imp Cancer Res Tech Compounds for targeting
IL108388A0 (en) * 1993-01-21 1994-04-12 Harvard College Amplified direction of effector groups to specific target cells in an animal
US5482698A (en) * 1993-04-22 1996-01-09 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin polymer conjugates
US6120768A (en) * 1993-05-17 2000-09-19 Immunomedics, Inc. Dota-biotin derivatives
IL109666A0 (en) * 1993-05-17 1994-08-26 Immunomedics Inc A targeting composition containing a biotin- or avidinprotein conjugate and methods for the use thereof
KR100361933B1 (ko) 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
CA2178476A1 (en) * 1993-12-07 1995-06-15 Neorx Corporation Pretargeting methods and compounds
WO1995015978A1 (en) * 1993-12-07 1995-06-15 Neorx Corporation Pretargeting methods and compounds
US6015897A (en) * 1993-12-07 2000-01-18 Neorx Corporation Biotinamido-n-methylglycyl-seryl-o-succinamido-benzyl dota
WO1995015770A1 (en) * 1993-12-09 1995-06-15 Neorx Corporation Pretargeting methods and compounds
IL112372A (en) * 1994-02-07 2001-08-26 Res Dev Foundation Non-viral vector for the delivery of genetic information to cells
US6908903B1 (en) 1994-12-07 2005-06-21 Aletheon Pharmaceuticals, Inc. Cluster clearing agents
US6172045B1 (en) 1994-12-07 2001-01-09 Neorx Corporation Cluster clearing agents
US5955605A (en) * 1995-02-21 1999-09-21 Neorx Corporation Biotinidase resistant biotin-DOTA conjugates
CA2224907A1 (en) 1995-07-25 1997-02-13 Introgene B.V. Methods and means for targeted gene delivery
DE69713336T2 (de) * 1996-03-30 2002-12-05 Science Park Raf S.P.A., Milano Verfahren zur Herstellung von aktivierten markierten tumorspezifischen T-Zellen und deren Verwendung in der Behandlung von Tumoren
US7011812B1 (en) 1996-05-03 2006-03-14 Immunomedics, Inc. Targeted combination immunotherapy of cancer and infectious diseases
IT1289728B1 (it) 1996-12-10 1998-10-16 Sorin Biomedica Cardio Spa Dispositivo di impianto e corredo che lo comprende
US7144991B2 (en) 1999-06-07 2006-12-05 Aletheon Pharmaceuticals, Inc. Streptavidin expressed gene fusions and methods of use thereof
US7109303B2 (en) 2000-02-15 2006-09-19 Fondazione Centro San Raffaele Del Monte Tabor Modified cytokines for use in cancer therapy
IT1317835B1 (it) 2000-02-15 2003-07-15 San Raffaele Centro Fond Citochine modificate per uso nella terapia del cancro.
US7309694B2 (en) 2000-02-15 2007-12-18 Fondazione Centro San Raffaele Del Monte Tabor Modified cytokines for use in cancer therapy
WO2001093914A2 (en) 2000-06-08 2001-12-13 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
DE60129741T2 (de) 2000-06-20 2008-04-30 Immunomedics, Inc. Zielgerichtete kombinationsimmuntherapie für krebs und infektionskrankheiten
ITRM20010079A1 (it) 2001-02-16 2002-08-16 Sigma Tau Ind Farmaceuti Amminoderivati della biotina e loro coniugati con chelanti macrociclici.
GB0209896D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
ITRM20030196A1 (it) 2003-04-24 2004-10-25 Sigma Tau Ind Farmaceuti Uso di reagenti per la preparazione di un medicamento
CA2682296C (en) 2007-04-04 2017-02-28 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Anti-epcam antibody and uses thereof
US12594341B2 (en) 2020-06-14 2026-04-07 Shimon Slavin Multifunctional immunotherapeutic monoclonal antibody complexes and conjugates

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6621586A (en) * 1985-11-18 1987-06-02 University Of Texas System, The Polychelating agents for image and spectral enhancement (and spectral shift)
US4863713A (en) * 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents

Also Published As

Publication number Publication date
IT1245748B (it) 1994-10-14
EP0496074A1 (en) 1992-07-29
IT9068053A1 (it) 1992-06-22
DE69123235T2 (de) 1997-06-05
EP0496074B1 (en) 1996-11-20
DE69123235D1 (de) 1997-01-02

Similar Documents

Publication Publication Date Title
IT9068053A0 (it) Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi e terapia di affezioni tumorali e suo impiego
IL93840A0 (en) Novel monoclonal antibody to novel antigen associated with human tumors
KR880700061A (ko) 인체 암종양과 관련된 항원에 대한 단클론성 항체
IT8319234A0 (it) Procedimento per la produzione di anticorpi monoclonali umani.
EP0161941A3 (en) Monoclonal antibody useful in the diagnosis of human stomach or breast cancer
FI912016L (fi) In vitro -menetelmä antigeenispesifisten ihmisen monoklonaalisten vasta-aineiden valmistamiseksi
FI960268L (fi) Menetelmä sairauden diagnosoimiseksi määrittämällä GAGE-tuumorihyljintäantigeenin prekursorien ilmentymistä
BR9608884A (pt) Anticorpos monoclonais humanos de alta afinidade específicos para proteína-F rsv
DE3783277D1 (de) Monoklonaler antikoerper gegen humanes lungenkarzinom.
DE69319662D1 (de) Monoklonale Antikörper gegen GP130-Protein
DE3854502D1 (de) Gegen hiv-antigene spezifischer monoklonaler antikörper.
DE3482905D1 (de) Monoklonale antikoerper gegen lungenkrebs des "nicht-kleine-zellen"-typs.
IT1207589B (it) Composizione di anticorpi monoclonali umani cross-protettivi.
NO870770L (no) FremgangsmŸte for fremstilling av monoklonale antistoffer.
ITGE930053A1 (it) Dispositivo per la fabbricazione di ovatte.
IT1243924B (it) Procedimento per la preparazione di dieteri
FI873606A7 (fi) Ihmisen glykoalbumiinin määrittämiseen käyttökelpoisia vasta-aineita.
DK717888D0 (da) Monoklonale antistoffer
IT1239065B (it) Anticorpo monoclonale che inibisce l'azione biologica del fattore piastrinico 4
DE3787239D1 (de) Komplementabhängiger zytolytischer monoklonaler Antikörper gegen Trichomonas vaginalis und seine therapeutische und diagnostische Verwendung.
IT8819526A0 (it) Intermedi e procedimenti per lapreparazione di composti tetrazolici antipercolestorolemici.
EP0207170A4 (en) Process for preparing human cancer-specific monoclonal antibody.
GR3015489T3 (en) Monoclonal antibodies and process for the diagnosis of phytophtora infections.
DE69324776D1 (de) Pharmazeutische Zusammensetzung die krebserkennende Antikörper enthält
IT1301815B1 (it) Anticorpi monoclonali umani contro l'antigene tumorale uk114 e cellulelinfocitarie e ibridomi per la loro produzione

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19981231